RT Journal Article
SR Electronic
T1 Iodine Symporter Targeting with <sup>124</sup>I/<sup>131</sup>I Theranostics
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 34S
OP 38S
DO 10.2967/jnumed.116.186866
VO 58
IS Supplement 2
A1 James Nagarajah
A1 Marcel Janssen
A1 Philipp Hetkamp
A1 Walter Jentzen
YR 2017
UL http://jnm.snmjournals.org/content/58/Supplement_2/34S.abstract
AB Theranostics, a modern approach combining therapeutics and diagnostics, is among the most promising concepts in nuclear medicine for optimizing and individualizing treatments for many cancer entities. Theranostics has been used in clinical routines in nuclear medicine for more than 60 y—as 131I for diagnostic and therapeutic purposes in thyroid diseases. In this minireview, we provide a survey of the use of 2 different radioiodine isotopes for targeting the sodium–iodine symporter in thyroid cancer and nonthyroidal neoplasms as well as a brief summary of theranostics for neuroendocrine neoplasms and metastatic castration-refractory prostate cancer. In particular, we discuss the role of 124I-based dosimetry in targeting of the sodium–iodine symporter and describe the clinical application of 124I dosimetry in a patient who had radioiodine-refractory thyroid cancer and who underwent a redifferentiation treatment with the mitogen-activated extracellular signal–related kinase kinase inhibitor trametinib.